|12th March 2015
The modern pharmaceutical market can be saturated with competing products, from biosimilars, to same in-class, to alternative MoA treatments. Standing out from the crowd can be tough; innovative and patient serving methods of differentiation are hard to come by. HCPs can struggle to find the right treatment for their patients and the cost of switching between products is often financially and emotionally high. Therefore, there is a need to personalise medicine for the individual; ensuring maximum efficacy, reducing conversion costs, as well as to be able to differentiate and position products within the treatment pathway.
When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’s disease and Alzheimer’s; these are prognosis biomarkers. As we explore and understand more and more of the human genome, we are discovering more and more biomarkers, not just limited to disease diagnosis. Biomarkers are being used to determine a person’s genetic predisposition to respond well to certain treatments; these are predictive biomarkers. Investment and utilisation of this tool is a trend that we have seen growing in 2014 and predict to hear even more about into 2015.
A crowded market of biologics treating a chronic disease with very similar efficacy and safety evidence, all fighting for market leader position.
Detection of a predictive biomarker present in 60% of all patients shows, through retrospective analysis of clinical data, that efficacy levels in this patient segment are greatly increased for Product X. 95% of these patients achieve the primary endpoint compared to 70% of the general population (and market average) and continue to achieve results well after the ‘average patient’ has switched between treatments.
By segmenting patients in this way, pharma companies can:
The identification of a favourable predictive biomarker can not only optimise the lifecycle of a product, but completely reshape marketing campaigns and pricing strategy. Commercial messaging developed around a patient subset with guaranteed superior results is hugely powerful, and can ignite key stakeholder engagement. Biomarkers influence regulatory positioning and can determine, to an extent, the placement of a product in the treatment pathway. Pricing can also be impacted; the inclusion of a ‘free’ biomarker diagnosis test is an option and some protection from price erosion in saturated markets may be possible.
Biomarkers do have their limitations of course, their success and approval is hugely dependant on the evidence gathered, and some marketers will fear removing potential customers by segmenting the market in this way. Despite this, pharma is becoming less reserved and beginning to see the true potential of this powerful scientific marketing tool. As knowledge in this area grows, and certain pharma companies lead by example, we anticipate greater investment in this field and a trend towards the utilisation of biomarkers in brand strategies.
|16th August 2019
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
|26th July 2019
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
|16th July 2019
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.